Hoth Therapeutics, Inc. (HOTH)

Last Closing Price: 1.86 (2023-06-02)

Company Description

Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is based in New York, United States.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-11.37M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.52
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -119.32%
Return on Assets (Trailing 12 Months) -103.71%
Current Ratio (Most Recent Fiscal Quarter) 9.98
Quick Ratio (Most Recent Fiscal Quarter) 9.98
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $3.56
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) $-10.55
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 3.30M
Free Float 2.95M
Market Capitalization $6.13M
Average Volume (Last 20 Days) 0.23M
Beta (Past 60 Months) 0.12
Percentage Held By Insiders (Latest Annual Proxy Report) 10.71%
Percentage Held By Institutions (Latest 13F Reports) 2.24%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%